Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sritha Moram"'
Autor:
Alexander L. Rakhmilevich, Noah W. Tsarovsky, Mildred Felder, Jen Zaborek, Sritha Moram, Amy K. Erbe, Alexander A. Pieper, Dan V. Spiegelman, Emily M. Cheng, Cole M. Witt, Willem W. Overwijk, Zachary S. Morris, Paul M. Sondel
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe majority of experimental approaches for cancer immunotherapy are tested against relatively small tumors in tumor-bearing mice, because in most cases advanced cancers are resistant to the treatments. In this study, we asked if even late-
Externí odkaz:
https://doaj.org/article/29d00bafc93a4a5eba1dd4bd66f05425
Autor:
Paul Sondel, Alexander Rakhmilevich, Anna Hoefges, Mildred Felder, Zachary Morris, Amy Erbe, Arika Feils, Luke Zangl, Ravi Patel, Jacquelyn Hank, Dan Spiegelman, Alexander Pieper, Sritha Moram
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ba7ea0b6a9b349449d5ef3b343985367
Autor:
Ravi Patel, Sritha Moram, Zachary S. Morris, Mildred Felder, Anna Hoefges, Jacquelyn A. Hank, Luke M. Zangl, Arika Feils, Dan Spiegelman, Amy K. Erbe, Alexander L. Rakhmilevich, Alexander A. Pieper, Paul M. Sondel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundWe, and others, have previously shown that the in-situ vaccine of hypomethylated CG-enriched oligodeoxynucleotide (CpG) with agonist anti-OX40 antibody (OX40) is effective at curing mice in the A20 lymphoma model [1–4]. In separate precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252ca648bc25d850bf91db85a1cc68d5
https://doaj.org/article/ba7ea0b6a9b349449d5ef3b343985367
https://doaj.org/article/ba7ea0b6a9b349449d5ef3b343985367